Homepage
Author:
Nasus Pharma, Ltd.
Posted Date:
May 1, 2026
Nasus Pharma to Participate in Upcoming Investor Conferences
Nasus Pharma, Ltd.
May 1, 2026
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
Nasus Pharma, Ltd.
March 25, 2026
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold
Nasus Pharma, Ltd.
March 16, 2026
Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
Nasus Pharma, Ltd.
March 9, 2026
Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
Nasus Pharma, Ltd.
March 9, 2026
Nasus Pharma to Participate in Upcoming Investor Conferences
Nasus Pharma, Ltd.
February 20, 2026
Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026
Nasus Pharma, Ltd.
February 17, 2026
Nasus Pharma Announces Closing of $15.0 Million Private Placement
Nasus Pharma, Ltd.
February 13, 2026
Nasus Pharma Announces Pricing of $15.0 Million Private Placement
Nasus Pharma, Ltd.
February 10, 2026
